Labetalol Hydrochloride

Therapeutic Segment Antihypertensive

CAS No. 32780-64-6

Regulatory Filing USDMF, CEP

Development Status DMF Filed

Molecule Type Small Molecule

Enquire Now

Mechanism of Action

Labetalol has both competitive alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity leading to reduced heart rate, decreased force of contraction, and dilation of blood vessels, resulting in lowered blood pressure.

Disclaimer: No information in this Catalog – including any reference to any product or service – constitutes an offer for sale or be constructed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, under Bolar Provision the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of patent scenario for their respective markets and will be responsible for all patent related liabilities.